Psilocybin May Change How Your Brain Communicates — New Imaging Data Shows How
If you've spent any time on social media lately, you've probably seen posts about psilocybin and the brain.
Conversations around new neuroscience research suggest the compound found in psychedelic mushrooms may temporarily make the brain more flexible, disrupting the usual, rigid communication patterns between brain networks.
The idea is compelling. But what does the new imaging data1 actually say?
About the study
Researchers recruited 28 healthy adults who had never used psychedelics before. Each person received both a very low control dose and a full 25 mg dose of psilocybin, one month apart.
Brain activity was measured during the dosing sessions using EEG (a tool that tracks electrical activity in the brain), and MRI scans were taken before and one month after each dose.
Psilocybin has been studied for years in the context of mental health, particularly for treatment-resistant depression and anxiety, but detailed brain imaging data on what it actually does inside a healthy, first-time brain has been limited.
This study was designed to fill that gap. The researchers were upfront that it was an early-stage, exploratory study; not a clinical trial, and not a treatment study.
Psilocybin made the brain's signals more varied & less predictable
One of the study's main findings involves something called brain entropy.
Entropy here refers to how varied and unpredictable the brain's electrical signals are. A high-entropy brain is generating a wide range of activity patterns. A low-entropy brain is running the same loops over and over.
At one and two hours after the 25 mg dose, right around the peak of the experience, participants showed a significant spike in brain entropy.
Their brains were producing more varied, less repetitive signals than usual. Researchers have theorized that certain mental health conditions may be linked to overly rigid, low-entropy brain states; psilocybin appears to temporarily push the brain in the opposite direction.
Importantly, none of this happened under the low control dose, which suggests the effect is specific to the active compound at a meaningful dose.
Some changes were still visible a month later
The acute spike in brain activity is notable on its own. But some of the study's most interesting findings are about what happened a month after dosing.
MRI scans revealed structural changes in two specific pathways connecting the prefrontal cortex (the brain's planning and decision-making hub) to deeper subcortical regions, specifically the striatum and the thalamus (a relay hub between the cortex and other brain structures).
The brain's networks also showed slightly less separation between networks at the one-month mark than at pre-dose baseline, which is referred to as modularity. This pattern has been observed in previous psilocybin research in people with depression, and in this study, decreased modularity was associated with higher well-being scores.
The structural changes in those two brain pathways were the more robust long-term finding.
The brain changes predicted how people felt weeks later
The size of the acute entropy spike (how much the brain "loosened up" during the experience) predicted how participants felt about their well-being a month later. The bigger the shift during the experience, the better people tended to feel afterward.
The study also found that next-day psychological insight played a role in that relationship.
Participants who felt they'd gained meaningful understanding about themselves or their lives the day after dosing tended to report better well-being at one month. Increases in cognitive flexibility (the ability to think about problems from new angles) were also observed.
This chain of effects is one reason researchers find psilocybin so scientifically interesting. The acute brain changes don't just reflect an unusual drug experience. They may be part of a mechanism that produces lasting psychological shifts.
Not a "brain reset" — what the researchers actually say
It would be easy to read these findings and conclude that psilocybin "resets" the brain, or that a single dose produces lasting neurological transformation. The researchers are careful to push back on that framing.
This was an early-stage study in 28 healthy volunteers. There were no patients, no clinical populations, and no therapeutic protocol. The sample size is small. The authors describe their work as a starting point for understanding what psilocybin does to the brain, not a conclusion.
The "brain reset" narrative, while catchy, oversimplifies what the data actually shows: a temporary shift into a more flexible brain state, some structural changes in specific brain pathways, and psychological improvements that warrant further investigation in larger, more diverse groups.
Why researchers are paying attention
The broader context here is a growing body of research into psychedelic-assisted therapy for conditions like treatment-resistant depression, PTSD, anxiety, and other brain-related issues.
The Nature Communications findings help fill in a key gap; if psilocybin can temporarily increase brain flexibility and reduce rigid network patterns, that may help explain why some patients in clinical trials report meaningful psychological shifts after just one or two sessions.
A separate case report in Frontiers in Neuroscience2 offers another perspective.
This was a case study of an octogenarian Japanese-American woman with a 10-year history of Alzheimer's disease, including five years of predominantly monosyllabic speech, chronic urinary incontinence, dependent mobility, and severe reduction in spontaneous communication. She received a single oral dose of 5 grams of psilocybin-containing mushrooms.
Approximately 19 hours after administration, she spontaneously began speaking in full autobiographical sentences, a conversation that lasted several hours.
In the days and weeks that followed, multiple clinically meaningful improvements were documented, including restoration of urinary continence, improved mobility, independent dressing, increased emotional responsiveness, sustained social interaction, and contextual memory retrieval.
A second supervised session one month later, using a lower 3-gram dose, was associated with greater verbal expression, spontaneous humor, and improved gait agility.
This is a single case, so of course it can't be generalized. But it may be possible that, even with advanced neurodegeneration, certain brain functions can become transiently accessible under the right conditions. Psilocybin may be a part of creating those conditions.
The takeaway
Neuroscientists now have some of the most detailed imaging data yet on what psilocybin actually does inside a living human brain.
The brain temporarily shifts into a more flexible state, with some structural and psychological changes that appear to linger.
The research is still early, but it's laying important groundwork for understanding why psychedelics are generating so much interest in mental health science.